Overview

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy
Phase:
Phase 2
Details
Lead Sponsor:
Alkermes, Inc.